TG101348

• CAT Number: I005561
• CAS Number: 936091-26-8
• Molecular Formula: C27H36N6O3S
• Molecular Weight: 524.68
• Purity: 98%
• Synonyms: Tg-101348; TG101348; SAR302503
• Target: JAK2/FLT3
• Target Protein: P36888
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: JAK2：3 nM (IC50) ; Flt3：15 nM (IC50)
• IUPAC Name: N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
• InChI: InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
• InChIKey: JOOXLOJCABQBSG-UHFFFAOYSA-N
• SMILES: CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4

TG101348（Cat No.:I005561）is an investigational drug that acts as a potent, selective inhibitor of the JAK2 (Janus kinase 2) enzyme, specifically targeting the JH2 domain of the kinase. JAK2 is involved in regulating hematopoiesis (blood cell production) and immune function. Mutations in JAK2, particularly the V617F mutation, are implicated in various hematologic malignancies, including myeloproliferative disorders like polycythemia vera and essential thrombocythemia. TG101348 works by inhibiting the aberrant activation of JAK2, reducing abnormal cell proliferation and improving disease outcomes. It is currently being evaluated in clinical trials for its efficacy and safety in treating JAK2-driven diseases.